Avenda Health’s Unfold AI prostate cancer mapping platform is now eligible for Medicare reimbursement across seven western U.S. states.
The coverage spans California, Arizona, Utah, Nevada, Oregon, Washington, and Idaho, and provides urologists in those states with clearer payment pathways for the software, the firm said. Physician reimbursement for Unfold AI began in 2025. The new fee schedule inclusion extends that coverage regionally in office-based settings, which have historically lagged behind hospital outpatient settings, according to Avenda.
Unfold AI combines patient bloodwork, MRI imaging, and biopsy results to generate a personalized 3D cancer map intended to help physicians assess tumor extent and inform treatment planning, Avenda said.
